BioPharma Dive January 12, 2025
The biotech recently received a green light from regulators in New Zealand and Hong Kong to begin human testing of its epigenetic silencing therapy.
Genetic medicine startup Tune Therapeutics has raised another $175 million to develop therapies capable of “tuning” genes to treat disease, rather than editing them by cutting or replacing DNA directly.
Tune disclosed the Series B round on Sunday, the eve of the J.P. Morgan Healthcare Conference, which regularly features as a curtain-raising meeting for the biotechnology and pharmaceutical sectors. It follows a busy week for private financing in biotech, adding to nearly $2 billion worth of investment announced by venture firms tracked by BioPharma Dive since Monday.
Tune’s lead therapy, dubbed Tune-401, is designed to treat...
Today's Sponsors
Today's Sponsor